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A  vast  majority  of  menopausal  women  suffer  from  vasomotor  symptoms,  such  as hot ﬂushes  and  night
sweats,  the mean  duration  of  which  may  be  up  to 7–10  years.  In addition  to a  decreased  quality  of  life,
vasomotor  symptoms  may  have  an  impact  on  overall  health.  Vasomotor  symptoms  are  associated  with
overactivity  of  the  sympathetic  nervous  system,  and  sympathetic  overdrive  in  turn  is associated  with
metabolic  syndrome,  which  is a known  risk  factor  for cardiovascular  disease.  Menopausal  hot  ﬂushes
have  a complex  relationship  to different  features  of the  metabolic  syndrome  and  not all  data  pointympathetic overactivity
enopause
etabolic syndrome
lood pressure
nsulin resistance
besity
towards  an  association  between  vasomotor  symptoms  and  metabolic  syndrome.  Thus,  it is  still  unclear
whether  vasomotor  symptoms  are  an independent  risk  factor  for  metabolic  syndrome.  Research  in  this
area  is constantly  evolving  and  we  present  here  the most  recent  data  on the  possible  association  between
menopausal  vasomotor  symptoms  and the metabolic  syndrome.
©  2017  Elsevier  B.V.  All  rights  reserved.
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. Introduction
Up to 80% of menopausal women suffer from vasomotor symp-
oms. Follow-up studies [1–3] have shown that the mean duration
hypoestrogenism due to the decline in ovarian function and they
are also associated with an overactivity of the sympathetic nervous
system [4]. The decrease in endogenous estradiol, either through
surgical or natural menopause, and an elevated central sympatheticf vasomotor symptoms is longer than previously thought, up to
–10 years. Despite the fact that vasomotor symptoms are very
ommon, the precise etiopathology behind them is still unclear.
asomotor symptoms are a profound physiological reaction to
∗ Corresponding author at: Eira Hospital, Laivurinkatu 29, 00150 Helsinki, Finland.
E-mail address: tuomikoski.pauliina@gmail.com (P. Tuomikoski).
ttp://dx.doi.org/10.1016/j.maturitas.2016.12.010
378-5122/© 2017 Elsevier B.V. All rights reserved.tone, mediated through alpha-2 adrenergic receptors, are associ-
ated with a narrowed thermoneutral zone in the thermoregulatory
center in the brain. These changes in temperature regulation in
symptomatic women cause small increases in core body tempera-
ture to trigger vasomotor symptoms, such as hot ﬂushes and night
sweats [4].
An abundance of evidence link chronic activation of the sym-
pathetic nervous system and metabolic disturbances [5]. Elevated
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Fig. 1. Complex interplay between vasomotor symptoms, estrogen wi
ympathetic tone may  result in altered vascular function [6],
hanges in blood pressure [7] and lipids [8], and development of
nsulin resistance [5]. The metabolic syndrome (MetS) is a cluster
f closely related risk factors for cardiovascular disease and type
 diabetes. These include increased blood pressure, dyslipidemia
raised triglycerides and lowered high-density lipoprotein choles-
erol), hyperglycemia and central obesity [9]. Prothrombotic and
roinﬂammatory states and insulin resistance are also related to
etS. The prevalence of MetS is increasing rapidly in line with the
rowing obesity epidemic [10]. Although weight gain at midlife is
ot primarily inﬂuenced by menopause [11], the hormonal changes
re associated with increased total and abdominal fat [12–14].
hese changes in the body composition are a risk factor for insulin
esistance and the progression of type 2 diabetes. Furthermore,
bdominal obesity may  be related to an adverse lipid proﬁle.
Vasomotor symptoms and MetS share a common nominator,
ympathetic overactivity (Fig. 1). Thus, menopausal women  with
asomotor symptoms could well be at risk for MetS. On the other
and, MetS may  also exacerbate sympathetic overdrive [15] and
erhaps worsen vasomotor symptoms. Obesity is a mediator both
n vasomotor symptoms and MetS and its’ interactions and the
ndocrine functions of the adipose tissue are targets for an abun-
ance of research. In this review we present the most recent
ndings on vasomotor symptoms and the MetS, especially with
egard to the persistence or severity of hot ﬂushes and the role of
he adipose tissue.
. Vasomotor symptoms and blood pressure
Menopause-associated alterations in the function of the auto-
omic nervous system may  contribute to the increase in blood
ressure [7]. According to a recent systematic review with pooled
nalysis (12 studies, 19 667 women) published in this Journal [16]
n 2015, systolic blood pressure tended to be higher in women
ith hot ﬂushes (mean difference 1.95 mmHg, 95% CI 0.27-3.63) or
ight sweats (mean difference 1.33 mmHg, 95% CI, 0.63-2.03). For
iastolic blood pressure, only night sweats were associated with
 higher mean (mean difference 0.55 mmHg  (95% CI, 0.19–0.91),
hen compared with women with no symptoms. Hot ﬂushes per se
id not confer an increased odds for hypertension, but night sweats
ere associated with a higher odds of hypertension compared to
hose without (OR 1.17, 95% CI: 1.04–1.31, one study) [16].strogen withdrawal and diﬀerent  features of 
al and different features of the metabolic syndrome. Based on [4,5,8].
Not all cross-sectional data are uniform on the detrimental
effects of vasomotor symptoms and blood pressure. One study
actually found that women with most frequent vasomotor symp-
toms during 24 h had lower systolic blood pressure [17]. Also data
on no association between vasomotor symptoms and blood pres-
sure exist e.g. [18]. Looking at different menopausal stages, the
effect of vasomotor symptoms on blood pressure seems mixed. In
a cross-sectional study on 590 perimenopausal women there was
no association between vasomotor symptoms and blood pressure
[19]. In another study both systolic and diastolic blood pressures
were signiﬁcantly higher in women with vasomotor symptoms
either <10 years or ≥10 years postmenopausal, when compared
with women without symptoms [20]. Of note, women  in both
studies [19,20] showing increased blood pressure with vasomo-
tor symptoms were overweight with a mean BMI  between 26 and
29 kg/m2. On the contrary, women in studies [17,18] showing lack
of association were lean with a mean BMI  ≤25 kg/m2.
As vasomotor symptoms tend to last for several years, the possi-
ble impact on different markers for cardiovascular disease may  be
best studied in a longitudinal setting. One of the recent reports from
the SWAN study elaborate on the association between vasomotor
symptoms and blood pressure [21]. In this study data on vasomotor
symptoms and blood pressure was  collected at each annual study
visit. The study included 2839 women  and mean follow-up was
8.2 years. Women  with ≥6 days with vasomotor symptoms during
the preceding two  weeks had greater increases in diastolic blood
pressure over time than did asymptomatic women, or those with
less symptoms. Also the risk of developing pre-hypertension or
hypertension during follow-up was  increased among these women
(hazard ratio of 1.39, 95% CI; 1.09–1.79) even after adjustment for
multiple covariates [21].
It seems that vasomotor symptoms may  be associated with
increased blood pressure. However, obesity may be a factor that
modulates this effect. More data are also needed regarding the
impact of the severity of vasomotor symptoms on blood pressure.
3. Vasomotor symptoms and lipidsIn accordance with blood pressure, vasomotor symptoms start-
ing already in premenopause may  not associate with lipids, glucose
levels or insulin sensitivity [22]. This was  detected in a Canadian
4-year follow-up study (n = 80) where vasomotor symptoms were
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ssessed with mailed questionnaires with 3 month intervals and
lood samples were taken annually. At the end of the follow-up the
tudy group consisted of only 37 women of whom 6 were asymp-
omatic and 31 symptomatic. Due to the small numbers and the fact
hat 88% of the women were symptomatic at some point, it may  be
mpossible to determine for certain the lack of associations [22]. A
ollow-up time of only four years may  also be too short to distin-
uish the impact of vasomotor symptoms on markers of metabolic
ealth. Indeed, in the SWAN study the presence and frequency
f vasomotor symptoms after 8 years was associated with higher
ipid and lipoprotein levels [23]. Overall, quality data on vasomo-
or symptoms and lipids seems scarce. In the pooled analysis by
ranco et al. [16] data on hot ﬂushes and lipids included consisted
f only two studies. A larger number of studies were analyzed for
ight sweats, and the meta-analysis showed that night sweats were
ssociated with signiﬁcantly increased levels of total cholesterol
0.17 mmol/L, 95%CI 0.03–0.31) and LDL-cholesterol (mean differ-
nce: 0.07 mmol/L, 95% CI 0.01–0.13) [16].
. Vasomotor symptoms and insulin resistance
Estrogen deﬁciency has been shown to alter insulin sensitivity
nd predispose to diabetes in animal models [24]. A recent sys-
ematic review on vasomotor symptoms and metabolic health in
eri- and postmenopausal women concluded that many studies on
asomotor symptoms and metabolic health were of too low qual-
ty and high heterogenicity to make deﬁnite conclusions [25]. In
he SWAN study cohort of 3075 women with 8 years of follow
p, hot ﬂushes were related to a higher HOMA-index, a measure
or insulin resistance [26]. This ﬁnding persisted after adjusting for
evels of estradiol and follicle-stimulating hormone. Similar associ-
tions were also observed for fasting glucose level. These ﬁndings
ere not supported by cross-sectional studies [27,28] where fasting
lucose and HOMA-index did not differ according to the presence of
asomotor symptoms [28] or according to the number or severity
f hot ﬂushes [27].
Vasomotor symptoms and insulin resistance were studied
ecently in 1547 Korean postmenopausal women [29]. In this cross-
ectional study, the severity of vasomotor symptoms was assessed
y the Menopausal rating scale, and 57% of the women reported
asomotor symptoms to some degree. The HOMA-index increased
ith the increasing severity of the symptoms (none, mild, moder-
te, severe). Although all study participants were normal weight,
he BMI  was signiﬁcantly higher in women with severe hot ﬂushes
ompared to woman without hot ﬂushes.
Mechanisms linking hot ﬂushes with insulin resistance remain
nknown. Vasomotor symptoms and insulin resistance share com-
on  risk factors, especially elevated BMI, and there are conﬂicting
ata on whether BMI  explains the positive association between
asomotor symptoms and insulin resistance [26,29–31]. Increased
ympathetic nerve activity has been linked to decreased glucose
ptake and insulin resistance as well [32]. However, the complex
nteractions between sympathetic nervous system, metabolism,
besity, hyperinsulinemia, and insulin resistance make it difﬁcult
o deﬁne, which is the primary factor leading to metabolic dysfunc-
ion.
. Vasomotor symptoms and obesity
Adipose tissue is an active endocrine organ, it synthe-
izes steroid hormones and several bioactive mediators, called
dipokines. Adipokines are able to regulate metabolism and other
ody functions, such as immunity, insulin resistance, blood pres-
ure, and lipid metabolism [33]. Central obesity is characterized
ith chronic low-grade inﬂammation of adipose tissue. This resultsn / Maturitas 97 (2017) 61–65 63
in impaired regulation of the normal adipokine secretion, endothe-
lial dysfunction and metabolic dysregulation [33].
Both epidemiologic and longitudinal studies have linked obesity
with hot ﬂushes [34–37]. This is contradictory to the traditional
assumption that adiposity protects from hot ﬂushes through
peripheral aromatization of androgens into estrogens. In the SWAN
longitudinal study, higher odds of hot ﬂushes in pre- and early per-
imenopause was  related to an adverse adipokine proﬁle (higher
leptin, lower adiponectin level). Increased level of macrophage
chemoattractant protein 1 was  also associated with higher odds of
night sweats [37]. Several smaller studies support the association
between hot ﬂushes and impaired adipokine secretion [38–40].
In postmenopausal women  screened for MetS, higher levels of
adiposin, leptin, resistin, insulin and HOMA-IR values and lower
adiponectin levels were associated with MetS [41]. These dif-
ferences were mainly observed among women with abdominal
obesity.
The mechanisms behind the association between adipokines
and hot ﬂushes are not clear, but adipokines have been shown to
inﬂuence the central nervous system, the body temperature [42,43]
as well as sympathetic nerve activity [32]. In recent years, the reg-
ulation of vascular tone and endothelial function by adipokines
released from the perivascular adipose tissue has also raised inter-
est [44]. The substances could in theory modulate vasomotor
function.
Thus, there is some support for the idea that adipokines may
be one mechanism linking increased adiposity, metabolic distur-
bances and hot ﬂushes in postmenopausal women.
6. Impact of severity or timing of vasomotor symptoms
The ﬁeld of menopause research is evolving and more research
is directed towards the impact of vasomotor symptoms. As regards
cardiovascular outcomes, a Finnish study found no signs of an
adverse cardiovascular risk proﬁle in recently postmenopausal
women with either mild, moderate or severe vasomotor symptoms
[45]. Similarly, in the KEEPS trial [46], hot ﬂushes or night sweats
were not associated with either the amount of coronary calcium
or intima-media thickness. Both studies included only lean women
and obesity may  indeed be a factor that modiﬁes the risk proﬁle
associated with vasomotor symptoms. Interestingly, long-lasting
vasomotor symptoms that begin already in the early menopausal
years are associated with a higher intima-media thickness when
compared with women who  traverse through menopause with a
low frequency of hot ﬂushes [47]. This indicates that the longevity
of vasomotor symptoms may  be of more signiﬁcance than just the
presence of hot ﬂushes.
7. Further research
More research on vasomotor symptoms and subsequent
metabolic and cardiovascular risk is needed. Majority of the data
available are cross-sectional and information on vasomotor symp-
toms is gathered through diaries or questionnaires, which are a
subject of recall bias [48]. Moreover, all vasomotor symptoms are
not subjectively observed by the women  [49]. Thus, future studies
need long-term follow-up and also to utilize objective measure-
ment of vasomotor symptoms.
The guidelines on postmenopausal hormone therapy use have
recommended the treatment to be directed to moderate to severe
symptoms and to be as short in duration as possible. From a car-
diovascular point of view, if vasomotor symptoms indeed are a risk
factor for metabolic disease, should also mild symptoms be treated?
Furthermore, due to the longevity of vasomotor symptoms, should
longer treatments be encouraged after all?
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. Summary
Menopausal vasomotor symptoms may  be associated with an
ncreased risk of MetS. More data are needed on the effect of
rospectively and objectively recorded vasomotor symptoms on
etabolic syndrome and other cardiovascular risk factors. More-
ver, physicians need to be observant when taking care of women
ith long-lasting hot ﬂushes and remember to screen them also at
 later age for underlying MetS or cardiovascular disease.
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